

Selected publications 2011-2016

Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. *Acta Neurol Scand.* 2016 Nov 27. doi: 10.1111/ane.12712.

Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. *Lancet.* 2016 Nov 23. pii: S0140-6736(16)32388-1. doi: 10.1016/S0140-6736(16)32388-1.

Magyari M, Koch-Henriksen N, Sørensen PS. The Danish Multiple Sclerosis Treatment Register. *Clin Epidemiol.* 2016 Oct 25;8:549-552.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. *J Neurol.* 2016 Dec;263(12):2484-2493.

Moberg JY, Magyari M, Koch-Henriksen N, Thygesen LC, Laursen B, Soelberg Sørensen P. Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. *J Neurol.* 2016 Nov;263(11):2229-2237.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. *Neurol Genet.* 2016 Aug 4;2(4):e87.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzner R, Siebner HR, Laursen B, Soelberg Sorensen P. High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. *Mult Scler.* 2016 Aug 1. pii: 1352458516661048

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. *Mult Scler.* 2017 Feb;23(2):234-241.

Sørensen PS, Sellebjerg F, Lycke J, Färkkilä M, Créange A, Lund CG, Schlupe M, Frederiksen JL, Stenager E, Pflieger C, Garde E, Kinnunen E, Marhardt K; RECYCLINE Study Investigators. Minocycline added to subcutaneous interferon β -1a in multiple sclerosis: randomized RECYCLINE study. *Eur J Neurol.* 2016 May;23(5):861-70.

Sørensen PS. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs? *Nat Rev Neurol.* 2016 Jan;12(1):5-6.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB. Association between age at onset of multiple sclerosis and vitamin D level-related factors. *Neurology.* 2016 Jan 5;86(1):88-93.

Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. *Mult Scler.* 2016 Jun;22(7):944-54.

Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB, ... Sørensen PS, McVean G. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. *Nat Genet.* 2015 Jul;47(7):717-26.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. *Mult Scler.* 2015 Nov;21(13):1723-9.

Sellebjerg F, Sørensen PS. Therapeutic interference with leukocyte recirculation in multiple sclerosis. *Eur J Neurol.* 2015 Mar;22(3):434-42.

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. *Mult Scler.* 2015 Mar;21(3):318-31.

Damotte V, Guillot-Noel L, Patsopoulos NA, Madireddy L, El Behi M; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, De Jager PL, Baranzini SE, Cournu-Rebeix I, Fontaine B. A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. *Genes Immun.* 2014 Mar;15(2):126-32.

Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, Sellebjerg F, Sørensen PS, Helin K, Issazadeh-Navikas S. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. *Nat Med.* 2014 Mar;20(3):272-82.

Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. *Neurology.* 2014 Feb 8;82(7):573-81.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. *J Neurol.* 2014 Apr;261(4):773-83.

Romme Christensen J, Ratzler R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, Siebner HR, Sorensen PS, Sellebjerg F. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. *Neurology.* 2014 Apr 29;82(17):1499-507.

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. *J Neurol.* 2014 Jun;261(6):1170-7.

Sorensen PS. New management algorithms in multiple sclerosis. *Curr Opin Neurol.* 2014 Jun;27(3):246-59.

International Multiple Sclerosis Genetics Consortium. Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. *Am J Hum Genet* 2013 Jun 6;92(6):854-65.

Magyari M, Koch-Henriksen N, Pflieger CC, Sørensen PS. Gender and autoimmune comorbidity in multiple sclerosis. *Mult Scler.* 2014 Feb 5;20(9):1244-1251

Magyari M, Koch-Henriksen N, Pflieger CC, Sørensen PS. Reproduction and the risk of multiple sclerosis. *Mult Scler* 2013 Oct;19(12):1604-9.

Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. *Mult Scler* 2013;19(7):877-84.

Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. *Mult Scler J* 2013;19(9):1226-9.

Christensen JR, Börnsen L, Rätzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F. Systemic inflammation in progressive multiple sclerosis involves follicular Thelper, Th17- and activated B-cells and correlates with progression. *PLoS One* 2013;8(3):e57820.

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Vigiotta V, Greenberg SJ. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. *J Neurol* 2013;260(4):1136-46.

Sellebjerg F, Krakauer M, Limborg S, Hesse D, Lund H, Langkilde A, Søndergaard HB, Sørensen PS. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. *PLoS One* 2012;7(6):e35927.

Sellebjerg F, Krakauer M, Khademi M, Olsson T, Sørensen PS. FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. *Clin Exp Immunol* 2012;170(2):149-55.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. *Mult Scler* 2012;18(2):143-52.

Dogonowski AM, Siebner HR, Sørensen PS, Wu X, Biswal B, Paulson OB, Dyrby TB, Skimminge A, Blinkenberg M, Madsen KH. Expanded functional coupling of subcortical **5 of 20** nuclei with the motor resting-state network in multiple sclerosis. *Mult Scler* 2013;19(5):559-66.

Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS. Correlation between anti-interferon-*beta* binding and neutralizing antibodies in interferon-*beta*-treated multiple sclerosis patients. *Eur J Neurol* 2012;19(10):1311-7.

Blinkenberg M, Akeson P, Sillesen H, Lövgård S, Sellebjerg F, Paulson OB, Siebner HR, Sørensen PS. Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. *Acta Neurol Scand* 2012;126(6):421-7.

Sellebjerg F, Hedegaard CJ, Krakauer M, Hesse D, Lund H, Nielsen CH, Søndergaard HB, Sørensen PS. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. *Mult Scler* 2012;18(3):305-13.

Blinkenberg M, Mathiesen HK, Tscherning T, Jønsson A, Svarer C, Holm S, Sellebjerg F, Paulson OB, Hanson LG, Sørensen PS. Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. *Neurol Res.* 2012;34(1):52-8.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, -- Oturai AB, -- Sellebjerg F, -- Sørensen PS, Søndergaard HB, -- Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature* 2011;476(7359):214-9.

Sørensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Søndergaard HB; SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon *beta*-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. *Lancet Neurol* 2011;10(8):691-701.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. *Mult Scler* 2011;17(9):1074-8.

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. *Lancet Neurol* 2011;10(4):329-37.

Sørensen PS, Koch-Henriksen N, Jensen PE. Neutralizing antibodies against interferon-*beta* do not predispose antibodies against natalizumab. *Neurology* 2011;76(8):759-60.